Anti-LCAT 抗体 [EPR1384Y] (ab51060)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR1384Y] to LCAT
- Suitable for: IP, WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-LCAT antibody [EPR1384Y]
LCAT 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR1384Y] to LCAT -
由来種
Rabbit -
アプリケーション
適用あり: IP, WB, IHC-Pmore details -
種交差性
交差種: Human -
免疫原
Synthetic peptide within Human LCAT (C terminal). The exact sequence is proprietary.
Database link: P04180 -
ポジティブ・コントロール
- WB: Human serum and plasma lysates IHC-P: Human brain and liver tissue IP: Human plasma
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
バッファー
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 0.05% BSA, 40% Glycerol (glycerin, glycerine), 59% PBS -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR1384Y -
アイソタイプ
IgG -
研究分野
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab51060の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IP |
1/20.
For unpurified use at 1/100. |
|
WB |
1/10000. Detects a band of approximately 62 kDa (predicted molecular weight: 50 kDa).
|
|
IHC-P |
1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
See IHC antigen retrieval protocols. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. |
特記事項 |
---|
IP
1/20. For unpurified use at 1/100. |
WB
1/10000. Detects a band of approximately 62 kDa (predicted molecular weight: 50 kDa). |
IHC-P
1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. See IHC antigen retrieval protocols. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. |
ターゲット情報
-
機能
Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines. Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms. -
組織特異性
Expressed mainly in brain, liver and testes. Secreted into plasma and cerebral spinal fluid. In liver, expressed in HEPG2 hepatocytes. -
関連疾患
Defects in LCAT are the cause of lecithin-cholesterol acyltransferase deficiency (LCATD) [MIM:245900]; also called Norum disease. LCATD is a disorder of lipoprotein metabolism characterized by inadequate esterification of plasmatic cholesterol. Two clinical forms are recognized: familial LCAT deficiency and fish-eye disease. Familial LCAT deficiency is associated with a complete absence of alpha and beta LCAT activities and results in esterification anomalies involving both HDL (alpha-LCAT activity) and LDL (beta-LCAT activity). It causes a typical triad of diffuse corneal opacities, target cell hemolytic anemia, and proteinuria with renal failure.
Defects in LCAT are a cause of fish-eye disease (FED) [MIM:136120]; also known as dyslipoproteinemic corneal dystrophy or alpha-LCAT deficiency. FED is due to a partial LCAT deficiency that affects only alpha-LCAT activity. It is characterized by low plasma HDL and corneal opacities due to accumulation of cholesterol deposits in the cornea ('fish-eye'). -
配列類似性
Belongs to the AB hydrolase superfamily. Lipase family. -
翻訳後修飾
O- and N-glycosylated. O-glycosylation on Thr-431 and Ser-433 consists of sialylated galactose beta 1-->3N-acetylgalactosamine structures. N-glycosylated sites contain sialylated triantennary and/or biantennary complex structures. -
細胞内局在
Secreted. Secreted into blood plasma. Produced in astrocytes and secreted into cerebral spinal fluid. - Information by UniProt
-
参照データベース
- Entrez Gene: 3931 Human
- Omim: 606967 Human
- SwissProt: P04180 Human
- Unigene: 387239 Human
-
別名
- LCAT antibody
- LCAT_HUMAN antibody
- Lecithin cholesterol acyltransferase antibody
see all
画像
-
Anti-LCAT antibody [EPR1384Y] (ab51060) at 1/10000 dilution (Purified) + Human plasma lysates at 15 µg
Secondary
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 50 kDa
Observed band size: 62 kDa why is the actual band size different from the predicted?Blocking/Diluting Buffer and concentration: 5% NFDM/TBST
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue sections labeling LCAT with purified ab51060 at 1/100 dilution (1.03 µg/mL). Heat mediated antigen retrieval was performed using Bond™ Epitope Retrieval Solution 2 (pH 9.0) . Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument. -
Anti-LCAT antibody [EPR1384Y] (ab51060) at 1/10000 dilution (unpurified) + Human serum at 10 µg
Secondary
Goat anti-Rabbit HRP at 1/2000 dilution
Predicted band size: 50 kDa
Observed band size: 62 kDa why is the actual band size different from the predicted? -
ab51060 (Purified) at 1/20 dilution (0.5ug) immunoprecipitating LCAT in Human plasma.
Lane 1 (input): Human plasma 10ug
Lane 2 (+): ab51060 & Human plasma
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab51060 in Human plasma
For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/1000 dilution.
Blocking and diluting buffer: 5% NFDM/TBST.50 kDa band in input lane should be human IgG heavy chain.
-
ab51060 (unpurified) at 1/100 dilution staining LCAT in paraffin embedded human brain tissue by Immunohistochemistry. Heat mediated antigen retrieval was performed before commencing with IHC staining protocol.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (5)
ab51060 は 5 報の論文で使用されています。
- Komatsu T et al. Two Cases of Acquired High-Density Lipoprotein Deficiency with Immunoglobulin G4-Related Lecithin-Cholesterol Acyltransferase Autoantibody. J Atheroscler Thromb N/A:N/A (2022). PubMed: 36384970
- Tian F et al. MiR-542-5p Inhibits Hyperglycemia and Hyperlipoidemia by Targeting FOXO1 in the Liver. Yonsei Med J 61:780-788 (2020). PubMed: 32882762
- Flores R et al. LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea. Biomolecules 9:N/A (2019). PubMed: 31779197
- Cubedo J et al. ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia. J Lipid Res 57:1059-73 (2016). PubMed: 27112635
- Bogan RL & Hennebold JD The reverse cholesterol transport system as a potential mediator of luteolysis in the primate corpus luteum. Reproduction 139:163-76 (2010). PubMed: 19776099